Benzinga | Feb 25, 2021 05:32PM EST

Nektar Therapeutics Q4 EPS $(0.65) Beats $(0.68) Estimate, Sales $23.46M Miss $30.01M Estimate

Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.68) by 4.41 percent. This is a 1.56 percent decrease over losses of $(0.64) per share from the same period last year. The company reported quarterly sales of $23.46 million which missed the analyst consensus estimate of $30.01 million by 21.82 percent. This is a 30.71 percent decrease over sales of $33.86 million the same period last year.